Frontlight ResearchEarly access
CompletedNo phase
Emulation of the RECORD3 Trial Using Healthcare Claims Data
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 149,248 people enrolled
- Started
- 13 Oct 2024
- Ended
- 15 Jun 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Rivaroxaban
- Enoxaparin
- Record updated
- 10 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- At least 18 years of age
- Scheduled to undergo elective total knee replacement
Who cannot take part
- Drug or alcohol abuse
- Concomitant use of protease inhibitors for the treatment of HIV
- Had a requirement for anticoagulant therapy that could not be stopped
- Concurrent use of both drugs
- Had active bleeding or high risk of bleeding
- Substantial liver disease
- Severe renal impairment (creatinine clearance <30 ml per minute)
- Pregnancy or breastfeeding
- Had contraindications for prophylaxis with enoxaparin
- Had planned intermittent pneumatic compression
Where in United States
- Brigham and Women's HospitalBoston, United States
About the trial
What the trial wants to find out
Investigators are building an empirical evidence base for real-world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real-world data analyses can be conducted with confidence and how to implement such studies.
The 2 groups in the trial
- Enoxaparin
Reference group
- Rivaroxaban
Exposure group
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 July 2026